fosphenytoin has been researched along with levetiracetam in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (13.89) | 29.6817 |
| 2010's | 14 (38.89) | 24.3611 |
| 2020's | 17 (47.22) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ebert, U; Löscher, W; Reissmüller, E | 1 |
| Bergin, AM; Connolly, M | 1 |
| Bialer, M | 1 |
| Farooq, MU; Kassab, MY; Lobeck, IN; Majid, A; Xie, Y | 1 |
| Trinka, E | 1 |
| Akiyama, T; Otsubo, H | 1 |
| Lindsell, CJ; Shutter, LA; Steinbaugh, LA; Szaflarski, JP | 1 |
| Bajwa, RP; Gross, TG; Pai, V; Skeens, M; Soni, S; Termuhlen, AM | 1 |
| Alldredge, B; Bell, R; Bleck, TP; Brophy, GM; Claassen, J; Glauser, T; LaRoche, SM; Riviello, JJ; Shutter, L; Sperling, MR; Treiman, DM; Vespa, PM | 1 |
| Al Sherbini, K; Jensen, MB; Sattar, A | 1 |
| Broglio, KR; Connor, JT; Elm, JJ | 1 |
| Bleck, T; Chamberlain, J; Cloyd, J; Cock, H; Connor, J; Elm, J; Fountain, N; Jones, E; Kapur, J; Lowenstein, D; Shinnar, S; Silbergleit, R; Treiman, D; Trinka, E | 1 |
| Bansal, S; Blalock, D; Carpenter, JL; Dean, NP; Kebede, T | 1 |
| Friese, R; Gruessner, A; Joseph, B; Khalil, M; Kulvatunyou, N; Latifi, R; O'Keeffe, T; Rhee, P; Wynne, J; Zangbar, B | 1 |
| Daidoji, H; Doi, K; Hashimoto, H; Hiruma, T; Inokuchi, R; Morimura, N; Nakamura, K; Naraba, H; Sonoo, T; Tokunaga, K | 1 |
| Priano, J; Schiel, J; Servati, N; Vilar, J | 1 |
| Gaínza-Lein, M; Lamb, N; Loddenkemper, T; Sánchez Fernández, I | 1 |
| Barsan, W; Chamberlain, JM; Cloyd, J; Cock, H; Connor, JT; Conwit, R; Elm, J; Fountain, N; Kapur, J; Lowenstein, D; Meinzer, C; Shinnar, S; Silbergleit, R | 1 |
| Kandasamy, S; Krishnamoorthi, N; Nalisetty, S; Sangaralingam, T; Sridharan, B; Vijayakumar, V | 1 |
| Appleton, RE | 1 |
| Babcock, L; Barsan, W; Bleck, TP; Chamberlain, JM; Cloyd, J; Cock, H; Connor, JT; Conwit, R; Elm, J; Fountain, NB; Holsti, M; Kapur, J; Lowenstein, D; Meinzer, C; Rogers, A; Shinnar, S; Silbergleit, R; Underwood, E | 1 |
| Ardinger, CE; Berger, KE; Dunn, EN; Haines, KM; Jackson Piercy, CE; Lee-Stubbs, RB; Matson, LM; McCarren, HS; McDonough, JH; Miller-Smith, SM; Whitten, KA | 1 |
| Madaan, P; Sahu, JK | 1 |
| Bleck, TP; Chamberlain, JM; Cloyd, JC; Cock, HR; Coles, LD; Conwit, RA; Elm, JJ; Fountain, NB; Kapur, J; Lowenstein, DH; Sathe, AG; Shinnar, S; Silbergleit, R | 1 |
| Panda, PK; Sharawat, IK | 1 |
| Babl, FE; Hirsch, LJ; Josephson, SA; Wu, K | 1 |
| Hayashi, T; Noguchi, Y; Tachi, T; Takaoka, M; Teramachi, H | 1 |
| Abend, NS; Amengual-Gual, M; Anderson, A; Arya, R; Brenton, JN; Carpenter, JL; Chapman, K; Clark, J; Farias-Moeller, R; Gaillard, WD; Gaínza-Lein, M; Glauser, T; Goldstein, JL; Goodkin, HP; Guerriero, RM; Kapur, K; Lai, YC; Loddenkemper, T; McDonough, TL; Mikati, MA; Morgan, LA; Novotny, EJ; Ostendorf, AP; Payne, ET; Peariso, K; Piantino, J; Riviello, JJ; Sannagowdara, K; Tasker, RC; Tchapyjnikov, D; Topjian, A; Vasquez, A; Wainwright, MS; Wilfong, A; Williams, K | 1 |
| Babcock, L; Brundage, RC; Chamberlain, JM; Cloyd, JC; Cock, HR; Coles, LD; Elm, JJ; Fountain, NB; Ivaturi, V; Kapur, J; Lowenstein, DH; Mishra, U; Sathe, AG; Shinnar, S; Silbergleit, R | 1 |
| Catenacci, V; Choong, K; Duffett, M; Hewitt, M; Jones, K; Klowak, JA; Rochwerg, B | 1 |
| Asami, M; Egawa, S; Hoshiyama, E; Inoue, Y; Kaneko, J; Kimura, A; Kondo, Y; Maruo, K; Marushima, A; Nakamura, K; Takahashi, Y; Yamada, T; Yonekawa, C | 1 |
| Gottlieb, M; Long, B | 1 |
| Clay, JL; Fountain, NB | 1 |
| Chamberlain, JM; Coralic, Z; Kapur, J; Olson, KR; Overbeek, D; Silbergleit, R | 1 |
| Asami, M; Egawa, S; Fukuda, Y; Hoshiyama, E; Inoue, Y; Ishikawa, E; Kaneko, J; Kimura, A; Kondo, Y; Maruo, K; Marushima, A; Matsumaru, Y; Mochizuki, M; Nakamoto, H; Nakamura, K; Takahashi, Y; Uchida, M; Unemoto, K; Yamada, T; Yonekawa, C | 1 |
8 review(s) available for fosphenytoin and levetiracetam
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
New antiepileptic drug therapies.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Dioxolanes; Epilepsy; Felbamate; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Isoxazoles; Lamotrigine; Levetiracetam; Nipecotic Acids; Oxcarbazepine; Phenylcarbamates; Phenytoin; Piracetam; Propylene Glycols; Thiazines; Tiagabine; Topiramate; Triazines; Vigabatrin; Zonisamide | 2002 |
Clinical pharmacology of parenteral use of antiepileptic drugs.
Topics: Anticonvulsants; Epilepsy; Humans; Infusions, Intravenous; Injections, Intravenous; Levetiracetam; Pharmaceutical Vehicles; Phenytoin; Piracetam; Solubility; Valproic Acid | 2007 |
What is the relative value of the standard anticonvulsants: Phenytoin and fosphenytoin, phenobarbital, valproate, and levetiracetam?
Topics: Anticonvulsants; Benzodiazepines; Humans; Levetiracetam; Phenobarbital; Phenytoin; Piracetam; Prodrugs; Status Epilepticus; Treatment Outcome; Valproic Acid | 2009 |
[Antiepileptic drugs in North America].
Topics: Anticonvulsants; Carbamazepine; Drug Approval; Fructose; Humans; Japan; Lamotrigine; Levetiracetam; Lorazepam; North America; Phenytoin; Piracetam; Topiramate; Triazines | 2010 |
Meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Cost-Benefit Analysis; Decision Support Techniques; Humans; Lacosamide; Levetiracetam; Phenobarbital; Phenytoin; Status Epilepticus; Treatment Failure; Valproic Acid | 2019 |
Levetiracetam Versus Phenytoin or Fosphenytoin for Second-Line Treatment of Pediatric Status Epilepticus: A Meta-Analysis.
Topics: Anticonvulsants; Child; Humans; Levetiracetam; Phenytoin; Status Epilepticus | 2021 |
A critical review of fosphenytoin sodium injection for the treatment of status epilepticus in adults and children.
Topics: Adult; Anticonvulsants; Child; Humans; Levetiracetam; Phenytoin; Status Epilepticus | 2022 |
10 trial(s) available for fosphenytoin and levetiracetam
| Article | Year |
|---|---|
Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Bayes Theorem; Child; Child, Preschool; Comparative Effectiveness Research; Early Termination of Clinical Trials; Emergency Service, Hospital; Humans; Intention to Treat Analysis; Levetiracetam; Middle Aged; Models, Statistical; Phenytoin; Piracetam; Randomized Controlled Trials as Topic; Research Design; Status Epilepticus; Treatment Outcome; Valproic Acid; Young Adult | 2013 |
The established status epilepticus trial 2013.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Child; Child, Preschool; Double-Blind Method; Humans; Levetiracetam; Middle Aged; Phenytoin; Piracetam; Research Design; Status Epilepticus; Treatment Outcome; Valproic Acid; Young Adult | 2013 |
Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Double-Blind Method; Drug Resistance; Female; Humans; Hypotension; Infusions, Intravenous; Injections, Intramuscular; Levetiracetam; Male; Middle Aged; Phenytoin; Status Epilepticus; Valproic Acid; Young Adult | 2019 |
Clinical Effectiveness of Levetiracetam Compared to Fosphenytoin in the Treatment of Benzodiazepine Refractory Convulsive Status Epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Child; Humans; Levetiracetam; Neoplasm Recurrence, Local; Phenytoin; Status Epilepticus; Treatment Outcome | 2020 |
Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial.
Topics: Adolescent; Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Infant; Levetiracetam; Male; Middle Aged; Phenytoin; Status Epilepticus; Valproic Acid; Young Adult | 2020 |
The association of patient weight and dose of fosphenytoin, levetiracetam, and valproic acid with treatment success in status epilepticus.
Topics: Adolescent; Adult; Anticonvulsants; Body Weight; Dose-Response Relationship, Drug; Female; Humans; Levetiracetam; Male; Phenytoin; Single-Blind Method; Status Epilepticus; Treatment Outcome; Valproic Acid; Young Adult | 2020 |
Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; Phenytoin; Protein Binding; Status Epilepticus; Valproic Acid | 2021 |
Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for status epilepticus: study protocol for a multicenter non-inferiority designed randomized control trial.
Topics: Adult; Anticonvulsants; Diazepam; Humans; Japan; Levetiracetam; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Phenytoin; Randomized Controlled Trials as Topic; Status Epilepticus; Treatment Outcome | 2021 |
Treatment of Toxin-Related Status Epilepticus With Levetiracetam, Fosphenytoin, or Valproate in Patients Enrolled in the Established Status Epilepticus Treatment Trial.
Topics: Adult; Alcoholism; Analgesics, Opioid; Anticonvulsants; Benzodiazepines; Child; Cocaine; Female; Humans; Levetiracetam; Male; Phenytoin; Prospective Studies; Seizures; Status Epilepticus; Substance Withdrawal Syndrome; Valproic Acid | 2022 |
Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for adult convulsive status epilepticus: a multicentre non-inferiority randomised control trial.
Topics: Adult; Anticonvulsants; Diazepam; Humans; Levetiracetam; Phenytoin; Seizures; Status Epilepticus; Treatment Outcome | 2023 |
18 other study(ies) available for fosphenytoin and levetiracetam
| Article | Year |
|---|---|
Anticonvulsant efficacy of gabapentin and levetiracetam in phenytoin-resistant kindled rats.
Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Evaluation; Drug Resistance; Female; Gabapentin; gamma-Aminobutyric Acid; Kindling, Neurologic; Levetiracetam; Phenytoin; Piracetam; Rats; Rats, Wistar; Seizures | 2000 |
Blood pressure changes after intravenous fosphenytoin and levetiracetam in patients with acute cerebral symptoms.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Chi-Square Distribution; Female; Humans; Hypotension; Levetiracetam; Male; Medical Records; Middle Aged; Patient Selection; Phenytoin; Piracetam; Regression Analysis; Retrospective Studies; Seizures; Treatment Outcome | 2009 |
Initial EEG predicts outcomes in a trial of levetiracetam vs. fosphenytoin for seizure prevention.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Injuries; Disability Evaluation; Electroencephalography; Female; Glasgow Outcome Scale; Humans; Levetiracetam; Linear Models; Male; Middle Aged; Phenytoin; Piracetam; Randomized Controlled Trials as Topic; Seizures; Statistics, Nonparametric; Subarachnoid Hemorrhage; Young Adult | 2012 |
Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Anticonvulsants; Busulfan; Child; Child, Preschool; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Levetiracetam; Phenytoin; Piracetam; Seizures; Transplantation Conditioning; Young Adult | 2012 |
Treatment of status epilepticus: an international survey of experts.
Topics: Administration, Intravenous; Adult; Anticonvulsants; Child; Consensus; Expert Testimony; Humans; Hypnotics and Sedatives; Levetiracetam; Lorazepam; Midazolam; Pentobarbital; Phenytoin; Piracetam; Propofol; Societies, Medical; Status Epilepticus; Surveys and Questionnaires; Valproic Acid | 2013 |
Survey of prophylactic antiseizure drug use for non-traumatic intracerebral hemorrhage.
Topics: Anticonvulsants; Brain; Cerebral Hemorrhage; Drug Prescriptions; Drug Utilization; Electroencephalography; Humans; Levetiracetam; Phenytoin; Piracetam; Practice Patterns, Physicians'; Seizures; Surveys and Questionnaires | 2013 |
Levetiracetam versus (fos)phenytoin for seizure prophylaxis in pediatric patients with intracranial hemorrhage.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Female; Humans; Incidence; Infant; Intracranial Hemorrhages; Levetiracetam; Male; Phenytoin; Piracetam; Primary Prevention; Retrospective Studies; Seizures; Treatment Outcome | 2014 |
Levetiracetam Prophylaxis for Post-traumatic Brain Injury Seizures is Ineffective: A Propensity Score Analysis.
Topics: Adolescent; Adult; Anticonvulsants; Brain Injuries, Traumatic; Chemoprevention; Databases, Factual; Female; Humans; Levetiracetam; Male; Middle Aged; Phenytoin; Piracetam; Propensity Score; Retrospective Studies; Seizures; Treatment Failure; Young Adult | 2016 |
Efficacy of levetiracetam versus fosphenytoin for the recurrence of seizures after status epilepticus.
Topics: Administration, Intravenous; Administration, Oral; Anticonvulsants; Blood Pressure; Databases, Factual; Diazepam; Drug Substitution; Emergency Medical Services; Female; Hospitals, General; Humans; Japan; Levetiracetam; Male; Middle Aged; Phenytoin; Piracetam; Recurrence; Retrospective Studies; Seizures; Status Epilepticus; Treatment Outcome | 2017 |
A cool side effect of valproic acid administration: Single dose-induced hypothermia.
Topics: Adult; Anticonvulsants; Humans; Hypothermia; Levetiracetam; Male; Phenytoin; Seizures; Valproic Acid | 2018 |
Second-line anticonvulsants for paediatric convulsive status epilepticus.
Topics: Anticonvulsants; Child; Double-Blind Method; Humans; Levetiracetam; Phenytoin; Status Epilepticus; Valproic Acid | 2020 |
Evaluation of fosphenytoin, levetiracetam, and propofol as treatments for nerve agent-induced seizures in pediatric and adult rats.
Topics: Age Factors; Animals; Anticonvulsants; Brain; Disease Models, Animal; Female; Levetiracetam; Male; Organothiophosphorus Compounds; Phenytoin; Propofol; Rats, Sprague-Dawley; Sarin; Sex Factors; Status Epilepticus | 2020 |
Levetiracetam for Benzodiazepine-Refractory Status Epilepticus.
Topics: Benzodiazepines; Humans; Levetiracetam; Phenytoin; Status Epilepticus; Treatment Outcome | 2020 |
Clinical Effectiveness of Levetiracetam Compared to Fosphenytoin in the Treatment of Benzodiazepine Refractory Convulsive Status Epilepticus: Correspondence.
Topics: Benzodiazepines; Humans; Levetiracetam; Phenytoin; Status Epilepticus; Treatment Outcome | 2021 |
Choosing Anticonvulsant Medications to Manage Status Epilepticus.
Topics: Adult; Anticonvulsants; Disease Management; Drug Therapy, Combination; Epilepsy, Generalized; Female; Humans; Levetiracetam; Midazolam; Phenytoin; Status Epilepticus; Valproic Acid | 2020 |
Antiepileptic combination therapy with Stevens-Johnson syndrome and toxic epidermal necrolysis: Analysis of a Japanese pharmacovigilance database.
Topics: Anticonvulsants; Carbamazepine; Clobazam; Clonazepam; Databases, Factual; Drug Therapy, Combination; Epilepsy; Gabapentin; Humans; Japan; Lacosamide; Lamotrigine; Levetiracetam; Lorazepam; Pharmacovigilance; Phenytoin; Stevens-Johnson Syndrome; Valproic Acid | 2020 |
First-line medication dosing in pediatric refractory status epilepticus.
Topics: Adolescent; Age Factors; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Resistant Epilepsy; Female; Guideline Adherence; Humans; Infant; Levetiracetam; Male; Multivariate Analysis; Phenobarbital; Phenytoin; Practice Guidelines as Topic; Proportional Hazards Models; Retrospective Studies; Sex Factors; Status Epilepticus; Time-to-Treatment | 2020 |
Levetiracetam compared with phenytoin or fosphenytoin in benzodiazepine-refractory pediatric status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Child; Humans; Levetiracetam; Phenytoin; Status Epilepticus | 2022 |